Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:32:09 ON 21 APR 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 16:32:22 ON 21 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 APR 2009  HIGHEST RN 1137276-53-9
DICTIONARY FILE UPDATES:  20 APR 2009  HIGHEST RN 1137276-53-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10595891narrow.str
```





```
chain nodes :
11  13  14
ring nodes :
1  2  3  4  5  6  7  8  9  10  15  16  17  18  19  20
chain bonds :
3-13  9-11  13-14  14-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  15-16  15-20  16-17  17-18
 18-19  19-20
exact/norm bonds :
3-13  5-7  6-10  7-8  8-9  9-10  9-11  13-14  14-15
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  15-16  15-20  16-17  17-18  18-19  19-20
isolated ring systems :
containing 1 :


G1:N,CH

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  13:CLASS  14:CLASS  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:32:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3299 TO ITERATE

 60.6% PROCESSED     2000 ITERATIONS                              12 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        62535 TO    69425
PROJECTED ANSWERS:             129 TO      661

L2           12 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:32:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    66812 TO ITERATE

100.0% PROCESSED    66812 ITERATIONS                             290 ANSWERS
SEARCH TIME: 00.00.01

L3          290 SEA SSS FUL L1

=> d scan

L3   290 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-
     piperidinyl)-1-propen-1-yl]-3-ethyl-
MF   C27 H30 N2 O3

Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1-piperazinyl]methyl]-3-ethyl-
MF C32 H42 N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-
MF C18 H13 Cl N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 6-(isocyanatophenylmethyl)-3-methyl-
MF C18 H14 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 290 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-2-
    naphthalenylmethyl]-
MF C30 H35 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 185.88 186.10

```
FILE 'CAPLUS' ENTERED AT 16:33:02 ON 21 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 21 Apr 2009  VOL 150 ISS 17
FILE LAST UPDATED: 20 Apr 2009  (20090420/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 16:32:09 ON 21 APR 2009)

     FILE 'REGISTRY' ENTERED AT 16:32:22 ON 21 APR 2009
L1             STRUCTURE UPLOADED
L2              12 S L1
L3             290 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 16:33:02 ON 21 APR 2009

=> s l3
L4             18 L3

=> s l4 and (pry<2007)
       5386808 PRY<2007
L5             11 L4 AND (PRY<2007)

=> d 1-11 ibib abs hitstr

L5   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2007:1361172  CAPLUS
DOCUMENT NUMBER:          148:33513
TITLE:                    Preparation of
                          N-[4-(naphthylalkyl)benzoyl]-β-alanine compounds
                          and analogs as glucagon receptor antagonists
INVENTOR(S):              Kim, Ronald M.; Parmee, Emma R.; Tan, Qiang; Yang,
                          Cangming; Lins, Ashley Rouse
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 76pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
```

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007136577	A2	20071129	WO 2007-US11390	20070511 <--
WO 2007136577	A3	20080110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2007254329	A1	20071129	AU 2007-254329	20070511 <--
CA 2650619	A1	20071129	CA 2007-2650619	20070511 <--
EP 2019585	A2	20090204	EP 2007-776992	20070511 <--

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.:			US 2006-800641P	P 20060516 <--
			WO 2007-US11390	W 20070511

OTHER SOURCE(S): MARPAT 148:33513
GI



AB The title compds. I [ring A = bicyclic aryl or 8-10 membered bicyclic heteroaryl containing 1-3 heteroatoms; R1 = (un)substituted alkyl or alkenyl; R2 = H, alkyl or haloalkyl; R3 = aryl, X(aryl), X(alkylaryl), etc.; X = O, S, SO, SO2; R4 = CH2CH2CO2R5, CH2CH(OH)CO2R4 or 5-tetrazolyl; R6 = H, halo, CN, NO2, etc.] which are glucagon receptor antagonists useful for treating type 2 diabetes and related conditions, were prepared E.g., a multi-step synthesis of (1R or 1S)-II, starting from 6-methoxy-2-bromonaphthalene and Me 4-formylbenzoate, was given. IC50 values for the compds. I are generally in the range of as low as 1 nM to as high as about 500 nM, and thus have utility as glucagon antagonists. Pharmaceutical compns. comprising the compds. I and methods of treatment are also included.

IT 959121-76-7P 959121-77-8P 959121-78-9P

959121-79-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[4-(naphthylalkyl)benzoyl]-β-alanine compds. and analogs as glucagon receptor antagonists useful in treatment and prevention of type 2 diabetes mellitus and related diseases)

RN 959121-76-7 CAPLUS
CN β-Alanine, N-[4-[(1R)-1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959121-77-8 CAPLUS
CN β-Alanine, N-[4-[(1S)-1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959121-78-9 CAPLUS
CN Benzoic acid, 4-[1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 959121-79-0 CAPLUS
CN Benzoic acid, 4-[1-(1,2-dihydro-2-oxo-6-quinolinyl)-4,4,4-trifluorobutyl]- (CA INDEX NAME)



L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:523430 CAPLUS
DOCUMENT NUMBER: 143:60003
TITLE: Preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Mabire, Dominique Jean-Pierre; Guillemont, Jerome Emile Georges; Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054210	A1	20050616	WO 2004-EP13164	20041118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004295059	A1	20050616	AU 2004-295059	20041118 <--
CA 2546657	A1	20050616	CA 2004-2546657	20041118 <--
EP 1709012	A1	20061011	EP 2004-819602	20041118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1890224	A	20070103	CN 2004-80035857	20041118 <--
BR 2004016532	A	20070109	BR 2004-16532	20041118 <--
JP 2007513101	T	20070524	JP 2006-541830	20041118 <--
IN 2006DN03071	A	20070810	IN 2006-DN3071	20060529 <--
US 20070129375	A1	20070607	US 2006-596086	20060530 <--
MX 2006006255	A	20060809	MX 2006-6255	20060602 <--
KR 2006118534	A	20061123	KR 2006-711234	20060608 <--
NO 2006003028	A	20060628	NO 2006-3028	20060628 <--
PRIORITY APPLN. INFO.:			EP 2003-78859 A	20031205 <--
			WO 2004-EP13164 W	20041118 <--

OTHER SOURCE(S): CASREACT 143:60003; MARPAT 143:60003
GI



I



II

AB The title compds. I [n = 0-2; X = N, CR5; R5 = H or taken together with R1 may form CH:CHCH:CH; R1 = alkyl, thienyl; R2 = H, OH, or taken together with R3 or R4 may form O; R3 = OH, OR8, SR9, etc.; R8 = alkyl, alkylcarbonyl, dialkylaminoalkyl; R9 = dialkylaminoalkyl; R4 = H, alkyl, furanyl, etc.; with the provision], useful for the treatment of a PARP mediated disorder, were prepared E.g., a multi-step synthesis of II, starting from 1-(4-amino-3-nitrophenyl)-2-methyl-1-propanone, was given. The exemplified compds. I were tested in an in vitro assay based on SPA technol. and in an in vitro filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.

IT 854523-82-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854523-82-3 CAPLUS

CN Formamide, N-[1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-phenylpropyl]- (CA INDEX NAME)



IT 854524-08-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854524-08-6 CAPLUS

CN 2(1H)-Quinolinone, 3-methyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:523424 CAPLUS
DOCUMENT NUMBER: 143:60001
TITLE: Preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome Emile Georges; Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054201	A1	20050616	WO 2004-EP13163	20041118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004295058	A1	20050616	AU 2004-295058	20041118 <--
CA 2546300	A1	20050616	CA 2004-2546300	20041118 <--
EP 1687277	A1	20060809	EP 2004-819601	20041118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1882547	A	20061220	CN 2004-80034176	20041118 <--
BR 2004016206	A	20061226	BR 2004-16206	20041118 <--
JP 2007511574	T	20070510	JP 2006-540338	20041118 <--
SG 150533	A1	20090330	SG 2009-1197	20041118 <--
US 20070072842	A1	20070329	US 2006-595891	20060518 <--
IN 2006DN02813	A	20070803	IN 2006-DN2813	20060518 <--
MX 2006005687	A	20060817	MX 2006-5687	20060519 <--
KR 2006115393	A	20061108	KR 2006-710201	20060525 <--
NO 2006002894	A	20060809	NO 2006-2894	20060620 <--

PRIORITY APPLN. INFO.:			
	WO 2003-EP13028	A	20031120 <--
	EP 2003-78860	A	20031205 <--
	WO 2003-EP130	A	20031120 <--
	WO 2004-EP13163	W	20041118 <--

OTHER SOURCE(S): CASREACT 143:60001; MARPAT 143:60001
GI



I



II

AB The title compds. I [n = 0-2; X = N, CR7; R7 = H or taken together with R1 may form CH:CHCH:CH; R1 = alkyl, thiophenyl; R2 = H, OH, alkyl, alkynyl or taken together with R3 may form O; R3 = OH, OR10, SR11, etc.; R10, R11 = CHO, alkyl, (alkyl)amino, etc.; R4-R6 = H, halo, trihalomethyl, etc.; with the provision], useful for the treatment of a PARP mediated disorder, were prepared E.g., a multi-step synthesis of II, starting from bromobenzene and 3-methyl-6-quinolinecarboxaldehyde, was given. The exemplified compds. I were tested in an in vitro assay based on SPA technol. and in an in vitro filtration assay assessing PARP-1 activity (data given). The pharmaceutical composition comprising the compound I is disclosed.

IT 854532-59-5P 854532-61-9P 854533-52-1P
854533-95-2P 854534-00-2P 854534-03-5P
854534-17-1P 854534-18-2P 854534-19-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854532-59-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]-3-ethyl- (CA INDEX NAME)



RN 854532-61-9 CAPLUS

CN 6-Quinolineacetonitrile, 1,2-dihydro-3-methyl-2-oxo-α-phenyl- (CA INDEX NAME)



RN 854533-52-1 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-95-2 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]- (CA INDEX NAME)



RN 854534-00-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(hydroxyphenylmethyl)- (CA INDEX NAME)



RN 854534-03-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-oxoethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-17-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-18-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-19-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)-4-piperidinylidenemethyl]-3-ethyl- (CA INDEX NAME)



IT 130346-68-8P 130346-69-9P 854532-58-4P
854532-60-8P 854532-62-0P 854532-63-1P
854532-64-2P 854532-65-3P 854532-66-4P
854532-67-5P 854532-69-7P 854532-70-0P
854532-71-1P 854532-72-2P 854532-73-3P
854532-74-4P 854532-75-5P 854532-76-6P
854532-77-7P 854532-78-8P 854532-79-9P
854532-80-2P 854532-81-3P 854532-82-4P
854532-83-5P 854532-84-6P 854532-85-7P
854532-86-8P 854532-87-9P 854532-89-1P
854532-92-6P 854532-93-7P 854532-94-8P
854532-95-9P 854532-96-0P 854532-97-1P
854532-98-2P 854533-00-9P 854533-02-1P
854533-04-3P 854533-06-5P 854533-07-6P
854533-09-8P 854533-14-5P 854533-16-7P
854533-18-9P 854533-20-3P 854533-21-4P
854533-23-6P 854533-25-8P 854533-27-0P
854533-29-2P 854533-30-5P 854533-31-6P
854533-32-7P 854533-33-8P 854533-34-9P
854533-35-0P 854533-36-1P 854533-37-2P
854533-38-3P 854533-39-4P 854533-40-7P
854533-41-8P 854533-42-9P 854533-43-0P
854533-44-1P 854533-45-2P 854533-46-3P
854533-47-4P 854533-48-5P 854533-49-6P
854533-51-0P 854533-53-2P 854533-54-3P
854533-55-4P 854533-56-5P 854533-57-6P
854533-58-7P 854533-59-8P 854533-60-1P
854533-62-3P 854533-65-6P 854533-67-8P
854533-69-0P 854533-71-4P 854533-73-6P
854533-75-8P 854533-79-2P 854533-81-6P
854533-83-8P 854533-85-0P 854533-87-2P
854533-89-4P 854533-91-8P 854533-93-0P
854533-97-4P 854533-98-5P 854533-99-6P
854534-01-3P 854534-02-4P 854534-04-6P
854534-05-7P 854534-06-8P 854534-07-9P
854534-08-0P 854534-09-1P 854534-10-4P
854534-11-5P 854534-12-6P 854534-13-7P
854534-14-8P 854534-15-9P 854534-16-0P
854534-20-6P 854534-21-7P 854534-22-8P
854534-23-9P 854534-24-0P 854534-25-1P
854534-26-2P 854534-27-3P 854534-28-4P
854534-29-5P 854534-30-8P 854534-31-9P
854534-32-0P 854534-33-1P 854535-35-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 130346-68-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 130346-69-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 854532-58-4 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(methylamino)phenylmethyl]- (CA INDEX NAME)



RN 854532-60-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(acetyloxy)phenylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-62-0 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 854532-63-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(dimethylamino)phenylmethyl]-3-methyl- (CA INDEX NAME)



RN 854532-64-2 CAPLUS
CN Urea, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N'-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 854532-65-3 CAPLUS
CN Acetamide, N-[2-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-2-phenylethyl]- (CA INDEX NAME)



RN 854532-66-4 CAPLUS
CN 2(1H)-Quinolinone, 6-(methoxyphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854532-67-5 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-1H-imidazol-5-yl)phenylmethyl]- (CA INDEX NAME)



RN 854532-69-7 CAPLUS
CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-ethyl- (CA INDEX NAME)



RN 854532-70-0 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]phenylmethyl]- (CA INDEX NAME)



RN 854532-71-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-2-propen-1-yl]-4-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854532-72-2 CAPLUS
CN Piperidinium, 4-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]-1,1-bis[(2E)-3-phenyl-2-propen-1-yl]-, chloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Cl⁻

RN 854532-73-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)



RN 854532-74-4 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 854532-75-5 CAPLUS
CN Formamide, N-[(2,3-dihydro-1,4-benzodioxin-6-yl)(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)



RN 854532-76-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-hydroxyethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-77-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-78-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-pyrrolidinyl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-79-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-80-2 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[phenyl[[3-(2-thienyl)propyl]amino]methyl]- (CA INDEX NAME)



RN 854532-81-3 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[phenyl[[3-(1H-pyrrol-1-yl)propyl]amino]methyl]- (CA INDEX NAME)



RN 854532-82-4 CAPLUS
CN Acetamide, N-[2-[[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]amino]ethyl]- (CA INDEX NAME)



RN 854532-83-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[phenyl[[3-(1-piperidinyl)propyl]amino]methyl]- (CA INDEX NAME)



RN 854532-84-6 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[[(3-oxo-3-phenylpropyl)amino]phenylmethyl]- (CA INDEX NAME)



RN 854532-85-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[[2-(dimethylamino)ethoxy]phenylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854532-86-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[[(2-hydroxyethyl)amino]phenylmethyl]-3-methyl- (CA INDEX NAME)



RN 854532-87-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 854532-89-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(1-piperidinyl)ethyl]-1-piperidinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854532-88-0
CMF C32 H41 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854532-92-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854532-93-7 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 854532-94-8 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[2-fluoro-4-(trifluoromethyl)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 854532-95-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[[4-[3-(dimethylamino)propoxy]phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854532-96-0 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 854532-97-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-oxo-1-piperidinyl)methyl]-3-ethyl- (CA INDEX NAME)



RN 854532-98-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-00-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(1-piperidinyl)ethyl]-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (1:3) (CA INDEX NAME)

CM 1

CRN 854532-99-3
CMF C31 H40 N4 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-02-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[[4-(cyclohexylmethyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)

CM 1

CRN 854533-01-0
CMF C31 H39 N3 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4

RN 854533-04-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[6-fluoro-3-(4-piperidinyl)-1H-indazol-1-yl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-06-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1-piperazinyl]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-05-4
CMF C32 H42 N4 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4

RN 854533-07-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-09-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[4-(6-fluoro-1H-indazol-3-yl)-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-14-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]amino]phenylmethyl]-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-13-4
CMF C31 H33 F N4 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-16-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[phenyl[[3-(1-piperidinyl)propyl]amino]methyl]-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-15-6
CMF C25 H32 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-18-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[3-(1-piperidinyl)propyl]amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-17-8
CMF C28 H35 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-20-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[1-(phenylmethyl)-3-piperidinyl]amino]methyl]-3-ethyl-, ethanedioate (2:5) (CA INDEX NAME)

CM 1

CRN 854533-19-0
CMF C32 H35 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-21-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[1,3-benzodioxol-5-yl[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-23-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl-, ethanedioate (2:3) (CA INDEX NAME)

CM 1

CRN 854533-22-5
CMF C24 H28 N2 O4



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-25-8 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[[[3-[methyl(phenylmethyl)amino]propyl]amino]phenylmethyl]-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-24-7
CMF C28 H32 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-27-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[[3-[methyl(phenylmethyl)amino]propyl]amino]methyl]-3-ethyl-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-26-9
CMF C31 H35 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-29-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[(2-methoxyethyl)amino]phenylmethyl]-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 854533-28-1
CMF C21 H24 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-30-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(3-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 854533-31-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-32-7 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-2-naphthalenylmethyl]- (CA INDEX NAME)



RN 854533-33-8 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(2-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 854533-34-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chloro-3-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-35-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,4-dimethylphenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-36-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[[4-(dimethylamino)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-37-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-38-3 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-fluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 854533-39-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,4-difluorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-40-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[[2-chloro-5-(trifluoromethyl)phenyl][4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-41-8 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 854533-42-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)[2-(dimethylamino)ethoxy]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-43-0 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[4H-1,2,4-triazol-4-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 854533-44-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[(2,6-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-45-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-46-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-methyl-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-47-4 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]-1-naphthalenylmethyl]- (CA INDEX NAME)



RN 854533-48-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)(4-oxo-1-piperidinyl)methyl]-3-ethyl-
(CA INDEX NAME)



RN 854533-49-6 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(4-methyl-1-piperazinyl)[3-
(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 854533-51-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[[2-(dimethylamino)ethoxy][3-
(trifluoromethyl)phenyl]methyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX
NAME)

CM 1

CRN 854533-50-9
CMF C23 H25 F3 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-53-2 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl](2-methylphenyl)methyl]- (CA INDEX NAME)



RN 854533-54-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3,4-dichlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-55-4 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-oxo-1-piperidinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-56-5 CAPLUS
CN 6-Quinolineacetonitrile, 1,2-dihydro-α,3-dimethyl-2-oxo-α-phenyl- (CA INDEX NAME)



RN 854533-57-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)[4-[(2-methoxyethyl)amino]-1-piperidinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 854533-58-7 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[[4-[(2-methoxyethyl)amino]-1-piperidinyl][3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 854533-59-8 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-60-1 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[1-phenyl-3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 854533-62-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)propyl]-3-ethyl- (CA INDEX NAME)



RN 854533-65-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-[3-(trifluoromethyl)phenyl]propyl]-3-ethyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 854533-64-5
CMF C23 H25 F3 N2 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 854533-67-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[3-(dimethylamino)-1-phenylpropyl]-3-ethyl- (CA INDEX NAME)



RN 854533-69-0 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-(phenyl-1-piperidinylmethyl)- (CA INDEX NAME)



RN 854533-71-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 854533-73-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 854533-75-8 CAPLUS
CN Formamide, N-[(3-ethyl-1,2-dihydro-2-oxo-6-quinolinyl)phenylmethyl]- (CA INDEX NAME)



RN 854533-79-2 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(3-methylphenyl)methyl]- (CA INDEX NAME)



RN 854533-81-6 CAPLUS
CN Formamide, N-[1,3-benzodioxol-5-yl(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)



RN 854533-83-8 CAPLUS
CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(formylamino)methyl]-, ethyl ester (CA INDEX NAME)



RN 854533-85-0 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(3-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 854533-87-2 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 854533-89-4 CAPLUS
CN Formamide, N-[3-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-1-phenylpropyl]- (CA INDEX NAME)



RN 854533-91-8 CAPLUS
CN Formamide, N-[(3-chlorophenyl)(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)



RN 854533-93-0 CAPLUS
CN Formamide, N-[(4-chlorophenyl)(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)methyl]- (CA INDEX NAME)



RN 854533-97-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[hydroxy(3-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 854533-98-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-hydroxy-2-phenylethyl)- (CA INDEX NAME)



RN 854533-99-6 CAPLUS
CN Benzoic acid, 4-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)hydroxymethyl]-, ethyl ester (CA INDEX NAME)



RN 854534-01-3 CAPLUS
CN 2(1H)-Quinolinone, 6-(1,3-benzodioxol-5-ylhydroxymethyl)-3-methyl- (CA INDEX NAME)



RN 854534-02-4 CAPLUS

CN 2(1H)-Quinolinone, 6-(1-hydroxy-1-phenyl-2-propyn-1-yl)-3-methyl- (CA INDEX NAME)



RN 854534-04-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-05-7 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 854534-06-8 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(2-oxo-2-phenylethyl)- (CA INDEX NAME)



RN 854534-07-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-cyclohexyl-1-piperazinyl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-08-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[3-(4-chlorophenyl)-3-(1H-imidazol-1-yl)propyl]-3-ethyl- (CA INDEX NAME)



RN 854534-09-1 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[2-(1H-imidazol-1-yl)-2-phenylethyl]- (CA INDEX NAME)



RN 854534-10-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-[1-(4-chlorophenyl)-2-(3-ethyl-1,2-dihydro-2-oxo-6-quinoxalinyl)ethyl]- (CA INDEX NAME)



RN 854534-11-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[2-(4-chlorophenyl)-2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-12-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)(4-methyl-1H-imidazol-1-yl)methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-13-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-14-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1-piperidinylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-15-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 854534-16-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-20-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-21-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-22-8 CAPLUS
CN 2(1H)-Quinolinone, 3-methyl-6-[(1-methyl-3-piperidinylidene)phenylmethyl]- (CA INDEX NAME)



RN 854534-23-9 CAPLUS
CN 2(1H)-Quinolinone, 5-[1-(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)-3-(dimethylamino)-1-propen-1-yl]-3-methyl- (CA INDEX NAME)



RN 854534-24-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-25-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1Z)-1-(4-chlorophenyl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-26-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1Z)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(dimethylamino)-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-27-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1E)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-28-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1Z)-3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-29-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-30-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[(2E)-3-phenyl-2-propen-1-yl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 854534-31-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)[1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-4-piperidinylidene]methyl]-3-ethyl- (CA INDEX NAME)



RN 854534-32-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 854534-33-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(1S)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1-piperidinyl)propyl]-3-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 854535-35-6 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



IT 854534-37-5P 854534-38-6P 854534-40-0P
854534-42-2P 854534-48-8P 854534-49-9P
854534-50-2P 854534-51-3P 854534-52-4P
854534-53-5P 854534-62-6P 854534-64-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854534-37-5 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-methyl- (CA INDEX NAME)



RN 854534-38-6 CAPLUS
CN Formamide, N-[(1,2-dihydro-3-methyl-2-oxo-6-quinolinyl)phenylmethyl]-N-methyl- (CA INDEX NAME)



RN 854534-40-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)hydroxymethyl]-3-ethyl- (CA INDEX NAME)



RN 854534-42-2 CAPLUS
CN 2(1H)-Quinolinone, 6-benzoyl-3-ethyl- (CA INDEX NAME)



RN 854534-48-8 CAPLUS
CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854534-49-9 CAPLUS
CN 2(1H)-Quinolinone, 6-(aminophenylmethyl)-3-methyl-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

RN 854534-50-2 CAPLUS
CN 2(1H)-Quinolinone, 6-(isocyanatophenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854534-51-3 CAPLUS
CN 2(1H)-Quinolinone, 6-(2-amino-1-phenylethyl)-3-methyl- (CA INDEX NAME)



RN 854534-52-4 CAPLUS
CN 2(1H)-Quinolinone, 6-(hydroxyphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854534-53-5 CAPLUS
CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-methyl- (CA INDEX NAME)



RN 854534-62-6 CAPLUS
CN 2(1H)-Quinolinone, 6-(chlorophenylmethyl)-3-ethyl- (CA INDEX NAME)



RN 854534-64-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)-4-piperidinylmethyl]-3-ethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:430796 CAPLUS
DOCUMENT NUMBER: 141:7139
TITLE: Preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis
INVENTOR(S): Ladouceur, Gaetan H.; Bear, Brian; Bi, Cheng; Brittelli, David R.; Burke, Michael J.; Chen, Gang;

Cook, James; Dumas, Jacques; Sibley, Robert; Turner, Michael R.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043950	A1	20040527	WO 2003-US36003	20031110 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505819	A1	20040527	CA 2003-2505819	20031110 <--
AU 2003290744	A1	20040603	AU 2003-290744	20031110 <--
EP 1565455	A1	20050824	EP 2003-783328	20031110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016169	A	20050927	BR 2003-16169	20031110 <--
CN 1738814	A	20060222	CN 2003-80108639	20031110 <--
JP 2006509840	T	20060323	JP 2005-507146	20031110 <--
MX 2005004779	A	20050722	MX 2005-4779	20050504 <--
US 20060004011	A1	20060105	US 2005-534215	20050506 <--
NO 2005002796	A	20050609	NO 2005-2796	20050609 <--

PRIORITY APPLN. INFO.:
US 2002-425490P P 20021112 <--
US 2003-460915P P 20030407 <--
US 2003-484202P P 20030630 <--
WO 2003-US36003 W 20031110 <--

OTHER SOURCE(S): MARPAT 141:7139
GI



I II

AB The invention relates to title compds. I [wherein Ar = 6-membered aromatic ring containing 0-2 N atoms; R1 and R2 = independently H, halo, CF3, acyl, piperidinyl, piperazinyl, morpholinyl, or (un)substituted alkyl, alkoxy, amino, pyrrolidinyl, Ph, etc.; R3 = H, alkyl, OH, NO2, NH2, alkylamino, alkoxyamino, or (un)substituted benzoylamino; R4 = H, OH, halo, CN, acyl, sulfamoyl, trialkylsiloxy, tetrazolyl, thienyl, pyrrolyl, pyrimidinyl,

oxazolyl, furanyl, or (un)substituted alkyl, alkenyl, alkynyl, alkoxy, amino, oxadiazolyl, Ph, pyridyl(oxy), carbamoyl; R11 and R12 = independently H, F, or Cl with the proviso that when one of R11 and R12 = F or Cl, the other must be H; and pharmaceutically acceptable salts and esters thereof]. The invention also relates to the use of I and their pharmaceutical compns. for treating hyperproliferative disorders and diseases associated with angiogenesis (no data). Examples include representative syntheses for compds. of the invention, pharmaceutical compns. comprising them, and tumor model assays (no specific data given). For instance, N-Boc-indole was coupled with di-Me oxalate using t-BuLi to give tert-Bu 2-[methoxy(oxo)acetyl]-1H-indole-1-carboxylate (72%). Cyclization of the dione with 1,2-phenylenediamine in AcOH afforded the quinoxalinone II (77%).

IT 694531-84-5P 694531-85-6P 694531-86-7P
694531-93-6P 694532-04-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiproliferative and angiogenesis inhibitor; preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with angiogenesis)

RN 694531-84-5 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 694531-85-6 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-[[4-(2-methoxyethyl)-1-piperazinyl]carbonyl]-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694531-86-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-piperidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694531-93-6 CAPLUS
CN 2(1H)-Quinoxalinone, 3-[3-amino-5-(1-pyrrolidinylcarbonyl)-1H-indol-2-yl]-6-benzoyl- (CA INDEX NAME)



RN 694532-04-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-amino-2-(7-benzoyl-3,4-dihydro-3-oxo-2-quinoxalinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:796538 CAPLUS
DOCUMENT NUMBER: 139:323440
TITLE: Preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomography.
INVENTOR(S): Lesage, Anne Simone Josephine; Bischoff, Francois Paul; Janssen, Cornelus Gerardus Maria; Lavreysen, Hilde
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003082350	A2	20031009	WO 2003-EP3240	20030326	<--	
WO 2003082350	A3	20040304				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
CA 2479109	A1	20031009	CA 2003-2479109	20030326	<--	
AU 2003226737	A1	20031013	AU 2003-226737	20030326	<--	
AU 2003226737	B2	20080904				
BR 2003008945	A	20050104	BR 2003-8945	20030326	<--	
EP 1492571	A2	20050105	EP 2003-745282	20030326	<--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
CN 1642580	A	20050720	CN 2003-807387	20030326	<--	
JP 2005524679	T	20050818	JP 2003-579882	20030326	<--	
NZ 535438	A	20060831	NZ 2003-535438	20030326	<--	
IN 2004DN02631	A	20050401	IN 2004-DN2631	20040908	<--	
US 20060083676	A1	20060420	US 2004-509069	20040924	<--	
US 7517517	B2	20090414				
MX 2004009435	A	20050125	MX 2004-9435	20040928	<--	
ZA 2004007820	A	20051011	ZA 2004-7820	20040928	<--	
NO 2004004635	A	20041027	NO 2004-4635	20041027	<--	
PRIORITY APPLN. INFO.:			EP 2002-76254	A 20020329	<--	
			WO 2003-EP3240	W 20030326	<--	

OTHER SOURCE(S): MARPAT 139:323440

GI



AB Radiolabeled title compds. [I, II; X = O, S, C(R6)2, NR7; Y = O, S; R1 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, thienyl, quinolinyl, etc.; R2 = H, halo, cyano, alkyl, amino, heterocyclyl, etc.; R3, R4 = H, halo, OH, cyano, alkyl, alkoxy, etc.; R2R3 = (CH2)3-6, Z4CH2CH2CH2, Z4CH2CH2, etc.; Z4 = O, S, SO2, NR11; R11 = H, alkyl, PhCH2, alkoxycarbonyl; R3R4 = (CH2)4, CH:CHCH:CH; R5 = H, cycloalkyl, piperidinyl, oxothienyl, tetrahydrothienyl, aralkyl, alkoxyalkyl, etc.; R6 = H, aryl, alkyl, aminoalkyl; R7 = amino, OH], were prepared Most preferred are radiolabeled compds. in which the radioactive isotope is selected from 3H, 11C and 18F. The invention also relates to their use in a diagnostic

method, in particular for marking and identifying a mGluR1 receptor in biol. material, as well as to their use for imaging an organ, in particular using positron emission tomog. (PET). Thus, title compound (III) was prepared by tritiation of the corresponding bromide in THF using tritium gas and Pd/C catalyst. The purified product showed specific activity of 25 Ci/mmol.

IT 409344-47-4P 409344-48-5P 409344-56-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of radiolabeled quinolines and quinolinones as metabotropic glutamate receptor mGluR1 antagonists for use in positron emission tomog.)

RN 409344-47-4 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)



RN 409344-48-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:275968 CAPLUS
DOCUMENT NUMBER: 136:309857
TITLE: Preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists
INVENTOR(S): Mabire, Dominique Jean-Pierre; Venet, Marc Gaston; Coupa, Sophie; Poncelet, Alain Philippe; Lesage, Anne Simone Josephine
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028837	A1	20020411	WO 2001-EP11135	20010925 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421782	A1	20020411	CA 2001-2421782	20010925 <--
AU 2001093847	A	20020415	AU 2001-93847	20010925 <--
BR 2001014253	A	20030701	BR 2001-14253	20010925 <--
EP 1332133	A1	20030806	EP 2001-974298	20010925 <--
EP 1332133	B1	20080709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002167	A2	20031028	HU 2003-2167	20010925 <--
JP 2004510764	T	20040408	JP 2002-532423	20010925 <--
NZ 524945	A	20050128	NZ 2001-524945	20010925 <--
EE 200300126	A	20050415	EE 2003-126	20010925 <--
CN 1703403	A	20051130	CN 2001-816717	20010925 <--
AU 2001293847	B2	20070524	AU 2001-293847	20010925 <--
AT 400558	T	20080715	AT 2001-974298	20010925 <--
ES 2309095	T3	20081216	ES 2001-974298	20010925 <--
KR 818965	B1	20080404	KR 2003-702014	20030211 <--
HR 2003000229	A1	20030630	HR 2003-229	20030324 <--
IN 2003MN00328	A	20050211	IN 2003-MN328	20030324 <--
BG 107672	A	20040130	BG 2003-107672	20030326 <--
ZA 2003002515	A	20040630	ZA 2003-2515	20030331 <--
NO 2003001474	A	20030505	NO 2003-1474	20030401 <--
NO 325079	B1	20080128		
MX 2003002907	A	20030624	MX 2003-2907	20030401 <--
US 20040082592	A1	20040429	US 2003-381987	20030814 <--
US 7115630	B2	20061003		
US 20050209273	A1	20050922	US 2005-133678	20050520 <--

PRIORITY APPLN. INFO.:		EP 2000-203419 A	20001002 <--
		WO 2001-EP11135 W	20010925 <--
		US 2003-381987 A3	20030814 <--

OTHER SOURCE(S): MARPAT 136:309857
GI



I



II



III

AB The title compds. [I or II; X = O, C(R6)2; (wherein R6 = H, aryl, alkyl, etc.); R1 = alkyl, aryl, thienyl, etc.; R2 = H, halo, CN, etc.; R3, R4 = H, alkyl; or R2 and R3 may be taken together to form (CH2)3, (CH2)4, CH:CHCH:CH, etc.; or R3 and R4 may be taken together to form CH:CHCH:CH, (CH2)4; R5 = H, cycloalkyl, piperidinyl, etc.; Y = O, S; or Y and R5 may be taken together to form CH:NN, N:NN, NCH:CH], useful for treating or preventing glutamate-induced diseases of the central nervous system, were prepared Thus, reacting cis-III [R = Cl] with SnMe4 in the presence of Pg(PPh3)4 in PhMe afforded 17% cis-III [R = Me] which showed antagonism at a dose of 2.5 mg/kg bodyweight in cold allodynia test in rats with a Bennett ligation.

IT 409344-47-4P 409344-48-5P 409344-56-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolines and quinolinones as metabotropic glutamate receptor antagonists)

RN 409344-47-4 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(2-phenylacetyl)- (CA INDEX NAME)



RN 409344-48-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-[2-(2-methoxyphenyl)acetyl]- (CA INDEX NAME)



RN 409344-56-5 CAPLUS
CN 2(1H)-Quinolinone, 3-ethyl-6-(1-oxo-3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:672545 CAPLUS
DOCUMENT NUMBER: 129:275932
ORIGINAL REFERENCE NO.: 129:56265a,56268a
TITLE: Preparation of 3-oxadiazolylquinoxaline derivatives having affinity to benzodiazepine receptor
INVENTOR(S): Ohno, Kazunori; Odai, Osamu; Furukawa, Kiyoshi; Oka, Makoto
PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842701	A1	19981001	WO 1998-JP827	19980227 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 2002241379	A	20020828	JP 1997-87646	19970321
AU 9861179	A	19981020	AU 1998-61179	19980227 <--
PRIORITY APPLN. INFO.:			JP 1997-87646 A	19970321 <--
			WO 1998-JP827 W	19980227 <--

OTHER SOURCE(S): MARPAT 129:275932
GI

I II

AB Novel 3-oxadiazolylquinoxaline derivs. represented by general formula (I;

wherein Het is oxadiazolyl; R1 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, lower alkenyl, lower alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or lower alkoxy; R2 is hydrogen, lower alkyl, trifluoromethyl, lower cycloalkyl, halogeno, hydroxy, lower alkoxy, cyano, nitro, acyl, optionally substituted benzoyl, amino, lower mono- or dialkylamino, lower alkoxycarbonylmethyloxy, lower mono- or dialkylaminocarbonylmethyloxy, or optionally substituted benzyloxy; and R3 is hydrogen, lower alkyl, lower cycloalkyl, halogeno, or lower alkoxy), which are useful as a medicine, in particular, which have a selective affinity for benzodiazepine receptors and are useful as a brain activator and a remedy for senile dementia and Alzheimer's disease. Thus, a solution of 1,2-dihydro-2-oxo-3-quinoxalinecarboxylic acid and N,N'-carbonyl diimidazole in DMF was heated with stirring for 3 h at 60°, followed by adding acetamidoxime, and the stirring was continued for another 1.5 h to give 52.6% the title compound (II; R1 = Me; R2 = H). The latter compound and I (R1 = Et, R2 = OMe) inhibited the binding of [3H]diazepam to synaptosome membrane fraction prepared from rat brain with IC50 of 11.5 and 1.41 nM, resp.

IT 213743-73-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazolylquinoxaline derivs. having affinity to benzodiazepine receptor as brain activators and remedies for senile dementia and Alzheimer's disease)

RN 213743-73-8 CAPLUS

CN 2(1H)-Quinoxalinone, 6-benzoyl-3-(3-ethyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:210752 CAPLUS
DOCUMENT NUMBER: 128:257445
ORIGINAL REFERENCE NO.: 128:50967a,50970a
TITLE: Preparation of indolylbenzoquinoxalinones and related compounds as protein kinase C inhibitors.
INVENTOR(S): Bergstrand, Hakan; Karabelas, Kostas; Sjo, Peter
PATENT ASSIGNEE(S): Astra Aktiebolag (Publ), Swed.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813368	A1	19980402	WO 1997-SE1582	19970919 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,				

KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
US, UZ, VN, YU, ZW
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG

IN	1997DE02638	A	20050311	IN 1997-DE2638		19970916 <--
TW	472045	B	20020111	TW 1997-86113549		19970918 <--
ZA	9708469	A	19980325	ZA 1997-8469		19970919 <--
CA	2265854	A1	19980402	CA 1997-2265854		19970919 <--
AU	9744775	A	19980417	AU 1997-44775		19970919 <--
AU	716279	B2	20000224			
EP	929551	A1	19990721	EP 1997-943259		19970919 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
NZ	334531	A	20000929	NZ 1997-334531		19970919 <--
US	6271231	B1	20010807	US 1997-981266		19971218 <--
US	20010025043	A1	20010927	US 2001-865231		20010525 <--
PRIORITY APPLN. INFO.:				SE 1996-3505	A	19960925 <--
				SE 1997-2747	A	19970718 <--
				WO 1997-SE1582	W	19970919 <--
				US 1997-981266	A3	19971218 <--

OTHER SOURCE(S): MARPAT 128:257445
GI



I

AB Title compds. [I; A, X, Y, Z = C, N; ≥2 of A, X, Y, Z = C; may be substituted and/or annulated; excluding 3-(1H-indol-3-yl)-1H-quinoxalin-2-one, 3-(2-methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and 3-(1,2-diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one], were prepared as protein kinase C inhibitors (no data). Thus, 1,2-phenylenediamine was stirred overnight with [1-[3-(1,3-dioxoisoindol-2-yl)propyl]-1H-indol-3-yl]oxoacetic acid 2,5-dioxopyrrolidin-1-yl ester (preparation given) in THF to give 3-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate. The latter was stirred with MeNH2 in THF/H2O to give 3=[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)indol-1-yl]propylammonium acetate.

IT 205377-77-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylbenzoquinoxalinones and related compds. as protein kinase C inhibitors)

RN 205377-77-1 CAPLUS

CN 2(1H)-Quinoxalinone, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-6-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 205377-76-0

CMF C26 H24 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:527663 CAPLUS
DOCUMENT NUMBER: 125:167994
ORIGINAL REFERENCE NO.: 125:31485a,31488a
TITLE: Preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders
INVENTOR(S): Venet, Marc Gaston; Mabire, Dominique Jean-Pierre; Sanz, Gerard Charles
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620200	A1	19960704	WO 1995-EP5173	19951221 <--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1995CA01685	A	20050304	IN 1995-CA1685	19951220 <--
CA 2207268	A1	19960704	CA 1995-2207268	19951221 <--
AU 9644362	A	19960719	AU 1996-44362	19951221 <--
AU 698199	B2	19981029		
EP 800524	A1	19971015	EP 1995-943237	19951221 <--
EP 800524	B1	20011031		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE

CN	1171789	A	19980128	CN	1995-197162	19951221 <--
CN	1085668	C	20020529			
JP	10511654	T	19981110	JP	1995-520222	19951221 <--
BR	9510504	A	19990601	BR	1995-10504	19951221 <--
RU	2165419	C2	20010420	RU	1997-112898	19951221 <--
AT	207924	T	20011115	AT	1995-943237	19951221 <--
PT	800524	T	20020429	PT	1995-943237	19951221 <--
ES	2166838	T3	20020501	ES	1995-943237	19951221 <--
PL	182956	B1	20020531	PL	1995-321041	19951221 <--
ZA	9510989	A	19970627	ZA	1995-10989	19951227 <--
IL	116577	A	20000229	IL	1995-116577	19951227 <--
US	5922734	A	19990713	US	1997-860239	19970616 <--
FI	9702794	A	19970627	FI	1997-2794	19970627 <--
NO	9703029	A	19970627	NO	1997-3029	19970627 <--
NO	311220	B1	20011029			

PRIORITY APPLN. INFO.: EP 1994-203773 A 19941228 <--
WO 1995-EP5173 W 19951221 <--

OTHER SOURCE(S): MARPAT 125:167994

GI



I

AB Title compds. [I; R = 3-(F3C)C6H4][II; R1 = H, NH2, alkyl; R2,R3 = H, halo, alkyl; X = O or S; 1 of Z1,Z2 = N and the other = CH] were prepared Thus, (R)-II (R1-R3 = H, X = O, Z1 = N, Z2 = CH) gave complete suppression of estradiol undecylate-induced vaginal keratinization in 50% of ovariectomized rats at 1.25mg/kg orally.

IT 180421-65-2P 180421-66-3P 180421-67-4P
180421-68-5P 180421-69-6P 180421-70-9P
180421-71-0P 180421-72-1P 180421-73-2P
180421-74-3P 180421-75-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-[triazolyl(3-trifluoromethylphenyl)methyl]-2-quinolin(thi)ones for treatment of keratinization disorders)

RN 180421-65-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180421-66-3 CAPLUS
CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180421-67-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-68-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 180421-69-6 CAPLUS
CN 2(1H)-Quinolinone, 6-[fluoro-1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-70-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 180421-71-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[2-methyl-1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 180421-72-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[1-(1H-1,2,4-triazol-1-yl)-1-[3-(trifluoromethyl)phenyl]pentyl]- (CA INDEX NAME)



RN 180421-73-2 CAPLUS
CN 2(1H)-Quinolinone, 8-methyl-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-74-3 CAPLUS
CN 2(1H)-Quinolinone, 5-chloro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 180421-75-4 CAPLUS
CN 2(1H)-Quinolinone, 8-fluoro-6-[1H-1,2,4-triazol-1-yl[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1990:612014 CAPLUS

DOCUMENT NUMBER: 113:212014
ORIGINAL REFERENCE NO.: 113:35835a,35838a
TITLE: Preparation of (1H-azol-1-ylmethyl)quinolines, -quinazolines, and -quinoxalines as drugs
INVENTOR(S): Freyne, Eddy Jean Edgard; Venet, Marc Gaston; Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard Charles
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 106 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 371564	A2	19900606	EP 1989-203014	19891128 <--
EP 371564	A3	19910529		
EP 371564	B1	19950712		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5028606	A	19910702	US 1989-434957	19891113 <--
US 5037829	A	19910806	US 1989-435120	19891113 <--
CA 2002864	A1	19900529	CA 1989-2002864	19891114 <--
CA 2002864	C	19991116		
DK 8905994	A	19900530	DK 1989-5994	19891128 <--
DK 172748	B1	19990628		
NO 8904734	A	19900530	NO 1989-4734	19891128 <--
NO 174509	B	19940207		
NO 174509	C	19940518		
AU 8945646	A	19900607	AU 1989-45646	19891128 <--
AU 620946	B2	19920227		
HU 52498	A2	19900728	HU 1989-6220	19891128 <--
HU 205106	B	19920330		
ZA 8909076	A	19910731	ZA 1989-9076	19891128 <--
SU 1780536	A3	19921207	SU 1989-4742543	19891128 <--
IL 92486	A	19930708	IL 1989-92486	19891128 <--
ES 2088889	T3	19961001	ES 1989-203014	19891128 <--
FI 101964	B	19980930	FI 1989-5687	19891128 <--
FI 101964	B1	19980930		
CN 1042912	A	19900613	CN 1989-108925	19891129 <--
CN 1033752	C	19970108		
JP 02223579	A	19900905	JP 1989-307793	19891129 <--
JP 2916181	B2	19990705		
US 5151421	A	19920929	US 1991-672298	19910320 <--
US 5185346	A	19930209	US 1991-704746	19910523 <--
US 5268380	A	19931207	US 1992-973871	19921110 <--
US 5441954	A	19950815	US 1993-131817	19931005 <--
CN 1106004	A	19950802	CN 1994-117801	19941102 <--
CN 1036002	C	19971001		
CN 1106005	A	19950802	CN 1994-117802	19941102 <--
CN 1036003	C	19971001		
US 5612354	A	19970318	US 1995-409551	19950323 <--

PRIORITY APPLN. INFO.:

GB 1988-27820	A	19881129 <--
GB 1988-27821	A	19881129 <--
GB 1988-27822	A	19881129 <--
US 1989-434205	B2	19891113 <--
US 1989-434957	A3	19891113 <--
US 1991-704746	A3	19910523 <--
US 1992-973871	A3	19921110 <--
US 1993-131817	A3	19931005 <--

OTHER SOURCE(S): MARPAT 113:212014

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R = H, alkyl; X1:X2 = CH:CH, CH:N, N:CH; Y = H, alkyl, cycloalkyl, alkenyl, alkynyl, (un)substituted aryl, aralkyl; Z = (un)substituted (oxo)quinolinyl, (oxo- or thioxo)quinazolinyl, (oxo- or dioxo)quinoxalinyl] were prepared as retinoic acid metabolism inhibitors, aromatase inhibitors, etc. Thus, 3,4-dihydroquinolin-2(1H)-one was stirred 2 h at 70° with BzCl in DMF containing AlCl3 and the product reduced by NaBH4 to give hydroxymethylquinolinone II (R1 = Ph, R2 = OH). II (R1 = Me, R2 = OH) was stirred overnight with SOCl2 in THF and the product II (R1 = Me, R2 = Cl) stirred overnight at 60-70° with 1H-imidazole in DMSO to give II (R1 = Me, R2 = imidazolo) which maintained plasma levels of i.v. administered all-trans-retinoic acid at ≥10 ng/mL in rats 2 h after oral administration of 40 mg/kg.

IT 120067-41-6P 130344-00-2P 130344-01-3P
130344-02-4P 130344-03-5P 130346-18-8P
130346-22-4P 130346-25-7P 130346-26-8P
130346-27-9P 130346-30-4P 130346-42-8P
130346-51-9P 130346-66-6P 130346-68-8P
130346-69-9P 130347-21-6P 130347-22-7P
130347-23-8P 130347-25-0P 130347-26-1P
130347-28-3P 130347-30-7P 130347-31-8P
130347-33-0P 130347-35-2P 130347-37-4P
130347-39-6P 130347-41-0P 130347-42-1P
130347-44-3P 130347-45-4P 130347-46-5P
130347-47-6P 130347-48-7P 130347-62-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as retinoate metabolism and aromatase inhibitor)

RN 120067-41-6 CAPLUS

CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130344-00-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130344-01-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130344-02-4 CAPLUS
CN 2(1H)-Quinolinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130344-03-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130346-18-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-methyl- (CA INDEX NAME)



RN 130346-22-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[3-(trifluoromethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)



RN 130346-25-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)



RN 130346-26-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)



RN 130346-27-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)



RN 130346-30-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-

(CA INDEX NAME)



RN 130346-42-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130346-51-9 CAPLUS
CN 2(1H)-Quinoxalinone, 6-(1H-imidazol-1-ylphenylmethyl)-3-phenyl- (CA INDEX NAME)



RN 130346-66-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)



RN 130346-68-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 130346-69-9 CAPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



RN 130347-21-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)



RN 130347-22-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)



RN 130347-23-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)



RN 130347-25-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-, 4-oxide (CA INDEX NAME)



RN 130347-26-1 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-28-3 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 130347-30-7 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)



RN 130347-31-8 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)



RN 130347-33-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-35-2 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl-, 4-oxide (CA INDEX NAME)



RN 130347-37-4 CAPLUS

CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl- (CA INDEX NAME)



RN 130347-39-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylpropyl)- (CA INDEX NAME)



RN 130347-41-0 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylethyl)- (CA INDEX NAME)



RN 130347-42-1 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)



RN 130347-44-3 CAPLUS
CN 2(1H)-Quinoxalinone, 3-benzoyl-6-(1H-imidazol-1-ylphenylmethyl)-, 4-oxide (CA INDEX NAME)



RN 130347-45-4 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-46-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-47-6 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)



RN 130347-48-7 CAPLUS
CN 2(1H)-Quinoxalinone, 3-phenyl-6-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 130347-62-5 CAPLUS
CN 2(1H)-Quinoxalinone, 6-[(3,4-dichlorophenyl)-1H-imidazol-1-ylmethyl]-3-phenyl- (CA INDEX NAME)



L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1989:407401 CAPLUS
DOCUMENT NUMBER: 111:7401
ORIGINAL REFERENCE NO.: 111:1422h,1423a
TITLE: Imidazole- or pyridine-containing carbostyrils as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors, their preparation, and pharmaceuticals containing them
INVENTOR(S): Walker, Keith A. M.; Bruno, John J.; Martinez, Gregory R.
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
SOURCE: U.S., 20 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4792561	A	19881220	US 1986-868845	19860529
US 4921862	A	19900501	US 1988-247134	19880921 <--
PRIORITY APPLN. INFO.:			US 1986-868845	A3 19860529 <--

OTHER SOURCE(S): CASREACT 111:7401; MARPAT 111:7401
GI



I

AB Title compds. I [X = R1CR2, cis- or trans-CR3:CR4; R1 = H when R2 = OH, or R1 = Ph, phenylalkyl when R2 = H, OH; Ph is optionally monosubstituted; or R1R2 = O, C1-6 alkylidene, (substituted) benzylidene; R3 = H, C1-6 alkyl; R4 = H; R3R4 = bond; n = 0-3; R = 1-imidazolyl; dotted line = optional covalent bond] are prepared as thromboxane synthetase and cAMP phosphodiesterase inhibitors for treatment of disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels (no data). A mixture of CuI 11.6, (Ph3P)2PdCl2 86, N-propargylimidazole (preparation given) 774 mg, and 6-bromo-3,4-dihydrocarbostyril 1.5 g was stirred in 10mL pyridine and 2 mL triethylamine at 100° for 48 h under N. The reaction mixture was then treated with saturated aqueous K2CO3, extracted with 10% MeOH in CH2Cl2, and worked up to give 6-[3-(imidazol-1-yl)-1-propyn-1-yl]-3,4-dihydrocarbostyril. The latter (502 mg) was stirred under H in the presence of 200 mg 10% Pd/C to give 6-[3-(imidazol-1-yl)propyl]-3,4-dihydrocarbostyril (II). A tablet was formulated containing II 25, cornstarch 20, spray-dried lactose 153, and Mg stearate 2 mg.

IT 120067-41-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cAMP phosphodiesterase and thromboxane synthetase inhibitors)

RN 120067-41-6 CAPLUS

CN 2(1H)-Quinolinone, 6-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.28	251.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.02	-9.02

FILE 'STNGUIDE' ENTERED AT 16:34:10 ON 21 APR 2009

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 17, 2009 (20090417/UP).

```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                     0.35     251.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -9.02

STN INTERNATIONAL LOGOFF AT 16:37:05 ON 21 APR 2009
```